4.09
3.54%
+0.14
After Hours:
4.089
-0.0010
-0.02%
Novavax, Inc. stock is currently priced at $4.09, with a 24-hour trading volume of 2.99M.
It has seen a +3.54% increased in the last 24 hours and a -13.16% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.99 pivot point. If it approaches the $4.21 resistance level, significant changes may occur.
Previous Close:
$3.95
Open:
$3.97
24h Volume:
2.99M
Market Cap:
$572.41M
Revenue:
$693.46M
Net Income/Loss:
$-545.06M
P/E Ratio:
-0.5634
EPS:
-7.26
Net Cash Flow:
$-772.77M
1W Performance:
+3.02%
1M Performance:
-13.16%
6M Performance:
-36.29%
1Y Performance:
-45.68%
Novavax, Inc. Stock (NVAX) Company Profile
Name
Novavax, Inc.
Sector
Industry
Phone
240-268-2000
Address
20 Firstfield Road, Gaithersburg, MD
Novavax, Inc. Stock (NVAX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
Jan-09-23 | Reiterated | B. Riley Securities | Buy |
Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
Dec-02-22 | Initiated | Jefferies | Hold |
Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
May-20-22 | Initiated | BofA Securities | Underperform |
Feb-23-22 | Reiterated | B. Riley Securities | Buy |
Feb-22-22 | Resumed | Jefferies | Buy |
Jan-21-22 | Initiated | Cowen | Outperform |
May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-14-20 | Initiated | Jefferies | Buy |
Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Jun-29-20 | Reiterated | B. Riley FBR | Buy |
Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
May-28-20 | Reiterated | B. Riley FBR | Buy |
May-12-20 | Reiterated | H.C. Wainwright | Buy |
Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
Nov-27-19 | Resumed | B. Riley FBR | Buy |
Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
Dec-11-18 | Initiated | Oppenheimer | Outperform |
Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax, Inc. Stock (NVAX) Latest News
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks Investment Research
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Zacks Investment Research
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
The Motley Fool
What's in Store for Biogen (BIIB) This Earnings Season?
Zacks Investment Research
Better Buy: Bluebird Bio Vs. Novavax
The Motley Fool
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
Zacks Investment Research
Novavax, Inc. Stock (NVAX) Financials Data
Novavax, Inc. (NVAX) Revenue 2024
NVAX reported a revenue (TTM) of $693.46 million for the quarter ending December 31, 2023, a -59.37% decline year-over-year.
Novavax, Inc. (NVAX) Net Income 2024
NVAX net income (TTM) was -$545.06 million for the quarter ending December 31, 2023, a +17.16% increase year-over-year.
Novavax, Inc. (NVAX) Cash Flow 2024
NVAX recorded a free cash flow (TTM) of -$772.77 million for the quarter ending December 31, 2023, a -51.85% decrease year-over-year.
Novavax, Inc. (NVAX) Earnings per Share 2024
NVAX earnings per share (TTM) was -$5.56 for the quarter ending December 31, 2023, a +33.81% growth year-over-year.
About Novavax, Inc.
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Cap:
|
Volume (24h):